OCA
JSPR icon

Octagon Capital Advisors’s Jasper Therapeutics JSPR Stock Holding History

Octagon Capital Advisors’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-287,500
Closed -$6.53M – 49
2024
Q2 		$6.53M Sell
287,500
-213,311
-43% -$5.12M 1.03% 28
2024
Q1 		$14.7M Buy
500,811
+54,000
+12% +$959K 1.76% 18
2023
Q4 		$3.53M Hold
446,811
– – 0.56% 25
2023
Q3 		$3.13M Hold
446,811
– – 0.48% 31
2023
Q2 		$6.12M Sell
446,811
-191,439
-30% -$2.84M 0.85% 24
2023
Q1 		$11.6M Buy
+638,250
New +$11.8M 1.66% 13

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Octagon Capital Advisors's JSPR Position: Q3 2024 in Review

Octagon Capital Advisors sold out of Jasper Therapeutics (JSPR) in Q3 2024, closing a stake of 287,500 shares — an estimated $6.53M sold.

Octagon Capital Advisors first reported a position in JSPR in Q1 2023 and held it in 6 quarters. The position peaked at $14.7M in Q1 2024. 81 funds tracked by Wall St. Rank hold JSPR as of Q3 2024.

  • Octagon Capital Advisors reported no remaining Jasper Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Octagon Capital Advisors sold 287,500 Jasper Therapeutics shares in Q3 2024, an estimated $6.53M.
  • Octagon Capital Advisors first reported a position in Jasper Therapeutics in Q1 2023 and held it in 6 quarters.
  • Octagon Capital Advisors's Jasper Therapeutics position peaked at $14.7M in Q1 2024.
  • 81 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q3 2024.

Based on Octagon Capital Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.